14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MAMA vs BHST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MAMA Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–1 Matrix Metrics)
MAMA Overall Winner
6-Pillar Tally: MAMA 4 – 2 BHST
Matrix Metrics: MAMA 9 – 1 BHST
As of Nov 20, 2026, Mama's Creations, Inc. (MAMA) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MAMA carries a Unified Composite Score of 39.0/100 (SELL) at $11.08 (36.9x Forward P/E, 5.2% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin).
Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. MAMA 39.0/100 SELL), MAMA captures the overall institutional head-to-head verdict (9–1 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -18.0% operating margin) and revenue trajectory (+55.0% vs. +3.8% YoY).
Technical & Structure Timing Caution: MAMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment77.0% of Rev ($27M)
90D Engineering Disclosures0 Published
Investor FAQ MAMA vs BHST Key Questions & Quantitative Answers
As of Nov 20, 2026, Mama's Creations, Inc. (MAMA) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MAMA carries a Unified Composite Score of 39.0/100 (SELL) at $11.08 (36.9x Forward P/E, 5.2% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. MAMA 39.0/100 SELL), MAMA captures the overall institutional head-to-head verdict (9–1 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -18.0% operating margin) and revenue trajectory (+55.0% vs. +3.8% YoY). Technical & Structure Timing Caution: MAMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MAMA leads the Growth & Scale pillar: MAMA posts +55.0% YoY revenue growth and +100.0% YoY earnings growth on $209M TTM revenue (24.3% gross margin, 5.2% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), MAMA cumulative revenue shifted +466.7% while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, MAMA deploys 19.1% of Rev ($40M) (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.
MAMA screens cheaper on headline valuation multiples. MAMA trades at 36.9x Forward P/E, 70.2x Trailing P/E, N/M PEG, and 1.9x EV/Revenue (8.3% FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MAMA (7.5% ROE) versus BHST (-142.5% ROE) capital efficiency.
In options market volatility and institutional positioning, MAMA carries 50.9% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.79β · 50% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.